Research programme: Dicer substrate siRNA therapeutics - Dicerna/Kyowa Hakko Kirin

Drug Profile

Research programme: Dicer substrate siRNA therapeutics - Dicerna/Kyowa Hakko Kirin

Latest Information Update: 14 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Developer Dicerna Pharmaceuticals; Kyowa Hakko Kirin
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Immunological disorders; Inflammation

Most Recent Events

  • 06 Jan 2015 Dicerna Pharmaceuticals has patent protection for dicer-substrate siRNA therapeutics in USA
  • 03 Jan 2013 Kyowa Hakko Kirin elects to advance a second therapeutic oncology drug candidate from the research to development
  • 08 Aug 2012 Dicerna receives milestone payment from Kyowa Hakko Kirin for second therapeutic oncology candidate achieving in vivo milestone activity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top